Ascentage Pharma Group (AAPG) Financials: Revenue & Earnings

AAPG price $14.70 -0.28 -1.90%

Ticker
AAPG
Price
$14.70
Change
-0.28 -1.90%
Market cap ?
$1.37B
P/E ?
-6.29
Forward P/E ?
4.40
Dividend yield ?
0.00%
Beta ?
0.66
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
41
Value
56
Quality
15
Growth
52

Stocklytics score rationale: value 56, quality 15, growth 52.

Financials

2016201720182019202020212022202320242025
766700063280006807000145130001245000027910000209711000221984000980650000558478193

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor…

Fair value

AAPG fair value $50.33. Price $14.70. Price is 71% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 55.57M. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 92.96M. Net debt -490.68M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare AAPG

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-03-31—-0.30—49.77M
2026-08-18-1.30-0.2244.85M53.63M
2026-03-24-0.65-0.8349.49M44.40M
2025-08-20-0.96—32.55M—
2025-03-27-1.000.0221.49M—
2024-08-220.31—115.41M—
2023-12-31-1.02—11.19M—
2023-08-21-0.81—19.57M—
2022-12-31-3.91—15.31M—
2022-08-26-0.89—13.84M—
2021-12-31-3.86—339.77K—
2021-08-24-0.94—2.00M—
2020-12-31-3.85—953.61K—
2020-08-18-0.89—378.20K—
2019-12-31-8.13—1.05M—
2019-06-30-8.15—1.06M—
2018-12-31-4.05—1.02M—
2018-06-30-0.02—21.33K—
2017-12-31-1.35—918.81K—
2017-06-30-0.04—40.50K—
2016-12-31-0.60—551.55K—
2016-06-30-0.63—576.65K—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-06-25Miyara FaicalOther0——
2026-05-21Zhai YifanBuy95.58K——
2026-05-21Zhai YifanBuy92.75K——
2026-05-21Zhai YifanSell95.58K——
2026-05-21Yang DajunBuy95.58K——
2026-05-21Yang DajunBuy92.75K——
2026-05-21Yang DajunSell92.75K——
2026-05-20Zhai YifanBuy298.19K——
2026-05-20Zhai YifanBuy298.19K$6.581.96M
2026-05-20Zhai YifanBuy215.00K——
2026-05-20Zhai YifanBuy214.99K$6.581.41M
2026-05-20Zhai YifanBuy103.36K——
2026-05-20Zhai YifanBuy103.36K$8.12839.32K
2026-05-20Zhai YifanBuy95.58K——
2026-05-20Zhai YifanBuy92.75K——
2026-05-20Yang DajunBuy298.19K$6.581.96M
2026-05-20Yang DajunBuy215.00K——
2026-05-20Yang DajunBuy214.99K$6.581.41M
2026-05-20Yang DajunBuy103.36K——
2026-05-20Yang DajunBuy103.36K$8.12839.32K
2026-05-20Yang DajunBuy95.58K——
2026-05-20Yang DajunBuy92.75K——
2026-05-20Yang DajunBuy298.19K——
2026-04-20Misra VeetBuy18.58K——
2026-03-18Misra VeetOther0——
2026-03-18Cao JinOther0——
2026-03-18Cao JinOther12.88K——
2026-03-18Zhai YifanOther0——
2026-03-18Zhai YifanOther0——
2026-03-18Zhai YifanOther0——
2026-03-18Zhai YifanOther0——
2026-03-18Zhai YifanOther103.36K$8.14841.38K
2026-03-18Zhai YifanOther103.36K——
2026-03-18Wei RenOther0——
2026-03-18Wei RenOther18.85K$8.14153.44K
2026-03-18Wei RenOther28.85K——
2026-03-18Ye ChangqingOther0——
2026-03-18Ye ChangqingOther28.85K——
2026-03-18Yu DebraOther27.96K——
2026-03-18Lu Simon DazhongOther0——
2026-03-18Lu Simon DazhongOther27.96K——
2026-03-18SIDRANSKY DAVIDOther0——
2026-03-18SIDRANSKY DAVIDOther28.85K——
2026-03-18Wang ShaomengOther0——
2026-03-18Wang ShaomengOther0——
2026-03-18Wang ShaomengOther0——
2026-03-18Wang ShaomengOther17.96K$8.14146.24K
2026-03-18Wang ShaomengOther27.96K——
2026-03-18LIPPMAN MARC EOther27.96K——
2026-03-18Knapp Thomas JOther0——
2026-03-18Knapp Thomas JOther38.94K$8.14316.96K
2026-03-18Knapp Thomas JOther38.94K——
2026-03-18Bozilenko MarinaOther27.96K——
2026-03-18Ye ChangqingOther56.55K$8.14460.32K
2026-03-18Ye ChangqingOther66.55K——
2026-03-18Bozilenko MarinaOther53.90K$8.14438.71K
2026-03-18Bozilenko MarinaOther63.90K——
2026-03-18Yang DajunOther0——
2026-03-18Yang DajunOther0——
2026-03-18Yang DajunOther0——
2026-03-18Yang DajunOther0——
2026-03-18Yang DajunOther103.36K$8.14841.38K
2026-03-18Yang DajunOther103.36K——
2026-03-18SIDRANSKY DAVIDOther56.55K$8.14460.32K
2026-03-18SIDRANSKY DAVIDOther66.55K——
2026-03-18Lu Simon DazhongOther53.90K$8.14438.71K
2026-03-18Lu Simon DazhongOther63.90K——
2026-03-18LIPPMAN MARC EOther0——
2026-03-18LIPPMAN MARC EOther53.90K$8.14438.71K
2026-03-18LIPPMAN MARC EOther63.90K——
2026-03-18Yu DebraOther53.90K$8.14438.71K
2026-03-18Yu DebraOther63.90K——

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 7, holders +1 vs prior quarter. Ownership 0.02%.

HolderSharesChangeChange %Value
POINT72 ASSET MANAGEMENT, L.P.13.84K-2.21K-13.80%243.05K
MORGAN STANLEY919421+84.54%16.14K
WELLS FARGO & COMPANY/MN200200New3.51K
EVERSOURCE WEALTH ADVISORS, LLC2400.00%421
UBS GROUP AG15-109-87.90%263
BLACKROCK, INC.66New105
CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD11New18
TOWER RESEARCH CAPITAL LLC (TRC)0-518-100.00%0
XY CAPITAL LTD0-13.01K-100.00%0

Earnings and financials

Ascentage Pharma Group International (AAPG) trades at $14.70, with a market cap of $1.37B and a trailing P/E of -6.29. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Financials

2016201720182019202020212022202320242025
766700063280006807000145130001245000027910000209711000221984000980650000558478193

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Ascentage Pharma Group (AAPG) Financials: Revenue & Earnings

AAPG$14.70-0.28 -1.90%

$1.37B

Market Cap

-6.29

P/E

4.40

Forward P/E

41

Score

Price History